NIM
ALNY icon

NXG Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

NXG Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,821
Closed -$411K – 77
2022
Q2 		$411K Sell
2,821
-2,699
-49% -$383K 0.04% 77
2022
Q1 		$901K Sell
5,520
-301
-5% -$45.9K 0.08% 60
2021
Q4 		$987K Sell
5,821
-383
-6% -$71.2K 0.1% 73
2021
Q3 		$1.17M Sell
6,204
-141
-2% -$26.4K 0.11% 67
2021
Q2 		$1.08M Sell
6,345
-160
-2% -$23.4K 0.1% 79
2021
Q1 		$918K Buy
6,505
+1,448
+29% +$218K 0.1% 86
2020
Q4 		$657K Buy
5,057
+89
+2% +$11.9K 0.07% 105
2020
Q3 		$723K Buy
4,968
+68
+1% +$9.66K 0.1% 70
2020
Q2 		$726K Sell
4,900
-637
-12% -$85.9K 0.08% 75
2020
Q1 		$603K Sell
5,537
-1,169
-17% -$135K 0.08% 65
2019
Q4 		$772K Buy
6,706
+99
+1% +$9.87K 0.04% 86
2019
Q3 		$531K Buy
+6,607
New +$523K 0.03% 96

Other funds holding ALNY

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NXG Investment Management's ALNY Position: Q3 2022 in Review

NXG Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 2,821 shares — an estimated $411K sold.

NXG Investment Management first reported a position in ALNY in Q3 2019 and held it in 12 quarters. The position peaked at $1.17M in Q3 2021. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • NXG Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • NXG Investment Management sold 2,821 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $411K.
  • NXG Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2019 and held it in 12 quarters.
  • NXG Investment Management's Alnylam Pharmaceuticals position peaked at $1.17M in Q3 2021.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on NXG Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.